Denali Therapeutics Inc. (DNLI)

Market Cap	3.35B
Revenue (ttm)	112.42M
Net Income (ttm)	-283.86M
Shares Out	123.35M
EPS (ttm)	-2.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	636,696
Open	27.06
Previous Close	27.25
Day's Range	26.35 - 27.63
52-Week Range	20.24 - 56.08
Beta	1.70
Analysts	Buy
Price Target	70.13 (+157.9%)
Earnings Date	Nov 2, 2022

About DNLI

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotr...

• Industry: Biotechnology
• IPO Date: Dec 8, 2017
• CEO: Ryan Watts
• Employees: 395
• Stock Exchange: NASDAQ
• Ticker Symbol: DNLI

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 21 analysts, the average rating for DNLI stock is "Buy." The 12-month stock price forecast is 70.13, which is an increase of 157.93% from the latest price.

Price Target

$70.13

(157.93% upside)

Analyst Consensus: Buy

Stock Forecasts